Chinese Journal of Tissue Engineering Research ›› 2010, Vol. 14 ›› Issue (45): 8535-8538.doi: 10.3969/j.issn.1673-8225.2010.45.041

Previous Articles     Next Articles

Transplantation of autologous bone marrow mesenchymal stem cells after culture via hepatic artery for one patient with decompensated cirrhosis

Jiao Hong-liang 1,2, Yang Bo1, Guan Fang-xia3, Li Jian-bin2, Zhan San-hua4, Du Ying5, Hu Xiang6, Chi Lian-kai3, Liang Shuo3, Shi Xin-yi3   

  1. 1 Department of Neurosurgery, First Affiliated Hospital, Zhengzhou University, Zhengzhou  450052, Henan Province, China; 2 Henan Province Red Cross Blood C enter, Zhengzhou  450014, Henan Province, China; 3 Department of Biomedical Engineering, Zhengzhou University, Zhengzhou  450052, Henan Province, China; 4 Department of Internal Medicine, Henan Province Hospital of Armed Police Force, Zhengzhou  450052, Henan Province, China; 5 Room of Microorganism and Immunology, Basic Medical College, Zhengzhou University, Zhengzhou   450052, Henan Province, China; 6 Shenzhen Beike Bio-Technology, Shenzhen  518000, Guangdong Province, China
  • Online:2010-11-05 Published:2010-11-05
  • Contact: Yang Bo, Professor, Doctoral supervisor, Department of Neurosurgery, First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, Henan Province, China yangbo96@126.com
  • About author:Jiao Hong-liang☆, Studying for doctorate, Department of Neurosurgery, First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, Henan Province, China; Henan Province Red Cross Blood Center, Zhengzhou 450014, Henan Province, China jhl787878@126.com
  • Supported by:

    the Major Subject Construction Program of 211 Engineering (III phase) of Zhengzhou University*; the Medical Science and Technology Innovation Talent Engineering Program of Henan Province, No. 2005018*

PDF

545

Abstract:

BACKGROUND: Bone marrow mesenchymal stem cells (BMSCs) in a specific environment can divide into hepatic stem cells and liver cells, which can participate in repair and reconstruction of liver structure and function.
OBJECTIVE: To explore the safety, feasibility and therapeutic effect of autologous BMSCs after culture transplantation via hepatic artery in treatment of cirrhosis.
METHODS: One patient with cirrhosis received autologous bone marrow mononuclear cell transplantation. Bone marrow mononuclear cells were isolated from autologous bone marrow and purified in vitro, and then cultured after 4 days. The stem cells were transplanted into the liver via hepatic artery. At 4 week after transplantation, serum albumin (ALB), cholinesterase (CHE), prothrombin activity (PTA), total bilirubin level (TBil), alanine aminotransferase (ALT), aspartate aminotransferase (AST), prothrombin time (PT), fibrinogen changes and complications and prognosis were observed.
RESULTS AND CONCLUSION: Numbers of BMSCs were significantly increased after culture. The index changes were respectively observed before and after transplantation. Pre-transplant: ALB, CHE, PTA, ALT, AST, PT, and fibrinogen were respectively 29. 43 g/L, 2 378.5 U/L, 47. 4%, 112.78 U/L, 79.36 U/L, 17.91 s, 2.01 g/L; 4 week after transplantation: 33.30 g/L,    2 866. 5 U/L, 55. 8%, 79.01U/L, 56.37 U/L, 16.26 s, and 2.35 g/L. No adverse event occurred following transplantation. Results suggest that after transplantation of autologous bone marrow, the liver function of patients was significantly improved. This method was safe and effective in the treatment of patients with decompensated cirrhosis. It can be used as a clinical treatment in patients with middle and advanced stage cirrhosis.

CLC Number: